Is it Worth Retaining NEOG Stock in Your Portfolio for Now?
Neogen leans on new product launches and 3M Food Safety integration to offset solvency strains and macro pressures.
| Ticker |
ILMN
|
| CIK | 0001110803 |
| SIC | 3826 |
| Sector | Manufacturing |
| Industry Category | Measuring And Control Equipment |
| Industry Group | Lab Analytical Instruments |
| Address | 5200 ILLUMINA WAY, SAN DIEGO, CA, 92122 |
| Website | illumina.com |
| Phone | 8582024500 |
| CEO | Francis A. deSouza |
| Employees | 11,500 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Is it Worth Retaining NEOG Stock in Your Portfolio for Now?Neogen leans on new product launches and 3M Food Safety integration to offset solvency strains and macro pressures. Phibro Animal Health Stock Climbs 59.6% YTD: What's Driving It?PAHC's 59% YTD surge rides on strong Animal Health momentum, booming vaccines and global gains despite the rising competition. Does Surging Genomics Consumables Demand Reshape The Bull Case For Illumina’s Recurring Revenue Engine (ILMN)?Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized medicine, with Illumina identified as a key player benefiting from advances in next-generation sequencing. An interesting angle is that consumables, kits, and reagents used in ongoing genomic experiments are expected to grow fastest, underscoring the importance of Illumina’s recurring revenue streams... Has Illumina’s Recent Rebound Created a Long Term Opportunity in 2025?If you are looking at Illumina and wondering whether today’s price really reflects its long term potential, you are not alone; this stock has gone from market darling to question mark and back again in many investors’ minds. After a big multi year slide that still leaves shares down about 62.3% over five years and 37.2% over three years, the recent 4.4% gain over the last month and a smaller 1.1% dip in the past week suggest investors are cautiously reassessing the risk reward balance. Part... ALGN Stock Rises on Thailand Launch of Invisalign With MAOBAlign Technology's Thailand debut of Invisalign with MAOB lifts shares and expands its Class II treatment options for increasing patients. |